Objectives: The question of an increase in the number of cases of zygomycosis (ZM) has been raised in American and European institutions. The use of voriconazole (Vori) as antifungal prophylaxis may correlate with this increase but that may not be the case in institutions in which Vori is not used prophylactically. We reviewed the evolution of ZM, before and after the introduction of Vori in our hospital. Methods: We retrospectively evaluated all cases of ZM in Gregorio Maraí±í³n Hospital from 1987 to 2005. Proven or probable diagnosis of ZM was performed according to established criteria (Ascioglu, CID 2002). Vori was introduced for therapeutic use in our hospital in 2002. Results: During the study period, 10 patients had proven or probable ZM (0.6 cases/year). The clinical forms and underlying conditions of the patients were 1 rhino-cerebral (kidney transplant), 2 sinuses (1 diabetes mellitus, 1 bone marrow aplasia), 3 cutaneous (1 diabetes mellitus under corticosteroid treatment, 1 heart transplant, 1 lymphoma), 3 pulmonary (1 COPD under corticosteroid treatment, 1 heart transplant, 1 leukaemia) and 1 cerebral (HIV infection). The cases had a sporadic distribution. Only one case of ZM occurred after the introduction of Vori. The consumption of Vori in 2004 was 1110 DDDs. Mean consumption per month was 88.6 DDDs (Standard deviation of 48.91 DDDs). Conclusions: Since 2002, therapy with voriconazole in our institution has not been associated with changes in the incidence of ZM.
Full conference title:
16th European Congress of Clinical Microbiology and Infectious Diseases
- ECCMID 16th (2006)